Novo Nordisk invests billions of dollars in post-semaglutide future
Novo Nordisk has been riding a wave of success in recent years, due in large part to GLP 1 analog semaglutide – but now is not the time to slack off on the work to bring new drugs to market, says Novo Nordisk’s CFO, Karsten Munk Knudsen at a teleconference on Wednesday in connection with the release of Novo’s 2021 financial figures.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Disappointing phase I results halt Novo's Dutch acquisition
For subscribers